GIP/GLP-1 Dual Agonist Formulations for Metabolic and Liver Disorders
Summary
The USPTO published patent application US20260097126A1 disclosing pharmaceutical formulations of small molecule GIP/GLP-1 dual receptor agonists for treating metabolic and liver disorders. The application (No. 18995773) was filed on July 18, 2023, by inventors Brian Lian, Geoffrey E. Barker, Maureen Barnes, Brahmachary Enugurthi, and Jake Gonzalez. The formulations include compounds classified under CPC codes A61K 47/548, A61K 9/0019, and others, with therapeutic applications targeting A61P 3/06 (metabolic disorders).
What changed
The USPTO published patent application US20260097126A1 disclosing novel pharmaceutical formulations combining GIP and GLP-1 dual receptor agonist compounds. The application covers small molecule formulations including excipients such as A61K 47/02, A61K 47/10, and A61K 47/26, with primary therapeutic indications for metabolic disorders (A61P 3/06) and liver disorders.
For pharmaceutical companies and biotech firms developing obesity, diabetes, or metabolic disease treatments, this patent application represents potential prior art and may affect freedom-to-operate analyses for competing dual-agonist programs. Companies should monitor the prosecution history and evaluate whether the disclosed formulation techniques could impact their own development strategies or require licensing considerations.
What to do next
- Monitor patent prosecution status for potential freedom-to-operate implications
- Evaluate formulation claims for competitive landscape assessment
- Review patent family for international filing strategies
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL FORMULATIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS
Application US20260097126A1 Kind: A1 Apr 09, 2026
Inventors
Brian Lian, Geoffrey E. Barker, Maureen Barnes, Brahmachary Enugurthi, Jake Gonzalez
Abstract
Disclosed herein are formulations of small molecule GIP/GLP-1 dual receptor agonists and uses thereof.
CPC Classifications
A61K 47/548 A61K 9/0019 A61K 47/02 A61K 47/10 A61K 47/26 A61P 3/06
Filing Date
2023-07-18
Application No.
18995773
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.